Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 17/20 | 0.43 |
| ▸ | MAOB | P27338 | 7/20 | 0.43 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.43 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933210 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HSD17B10KDM1AMAOBMAOA | |
| SCHEMBL19366623 | 1.00 | ALDH1A1 (0.44) | ALDH1A1HSD17B10KDM1AMAOBMAOA | |
| SCHEMBL1459410 | 0.97 | ALDH1A1 (0.42) | ALDH1A1HSD17B10KDM1AMAOBMAOA | |
| SCHEMBL2606443 | 0.88 | ALDH1A1 (0.67) | ALDH1A1HSD17B10KDM1AMAOBMAOA | |
| SCHEMBL8487925 | 0.86 | EPHX2 (0.42) | ALDH1A1HSD17B10KDM1AMAOBMAOA | |
| SCHEMBL24267657 | 0.84 | KDM1A (0.36) | ALDH1A1HSD17B10KDM1AMAOBMAOA | |
| SCHEMBL955079 | 0.84 | KDM1A (0.36) | ALDH1A1HSD17B10KDM1AMAOBMAOA | |
| SCHEMBL40608 | 0.84 | KMT2A (0.36) | ALDH1A1HSD17B10KDM1AMAOBMAOA | |
| Hydrochloric Acid SCHEMBL30556192 | 0.82 | KDM1A (0.38) | ALDH1A1HSD17B10KDM1AMAOBMAOA | |
| SCHEMBL71386 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11382872-B2 | LSD1 inhibitors as skeletal muscle hypertrophy inducers | CYTOO (FR) | 2022-07-12 | — | — | US | disclosed |
| US-20200054578-A1 | LSD1 INHIBITORS AS SKELETAL MUSCLE HYPERTROPHY INDUCERS | CYTOO (FR) | 2020-02-20 | — | — | US | disclosed |
| EP-3495349-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2019-06-12 | — | — | EP | disclosed |
| WO-2019075327-A1 | TREATING MERKEL CELL CARCINOMA | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11382872-B2 | LSD1 inhibitors as skeletal muscle hypertrophy inducers | KDM1B, CPT1B, KDM1A | ALDH1A1 1994/4885HSD17B10 841/4885KDM1A 3/4885 |
| US-20200054578-A1 | LSD1 INHIBITORS AS SKELETAL MUSCLE HYPERTROPHY INDUCERS | KDM1B, KDM1A, CPT1B | ALDH1A1 2925/4885HSD17B10 1278/4885KDM1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.